Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer.

Autor: Liu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Yoke LH; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA., Bhattacharyya P; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Hematology, University of Washington, Seattle, Washington, USA., Cheng GS; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington, USA., Escobar ZK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; School of Pharmacy, University of Washington, Seattle, Washington, USA., Ghiuzeli C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Hematology, University of Washington, Seattle, Washington, USA., McCulloch DJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Pergam SA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Roychoudhury P; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA., Tverdek F; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; School of Pharmacy, University of Washington, Seattle, Washington, USA., Schiffer JT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Ford ES; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2023 Jun 06; Vol. 10 (6), pp. ofad306. Date of Electronic Publication: 2023 Jun 06 (Print Publication: 2023).
DOI: 10.1093/ofid/ofad306
Abstrakt: Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir.
Competing Interests: Potential conflicts of interest. C. L. serves as an investigator for a clinical trial sponsored by Pfizer. R. D. C. has received research funding and consulting/honoraria from Pfizer. All other authors report no potential conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje